Zogenix's Fintepla Associated With Improvements in Seizure Control, Executive Functions In Childhood Epilepsy Disorder

Zogenix Inc ZGNX has announced new data showing the positive impact of treatment with Fintepla (fenfluramine) on everyday executive function for children and young adults with Lennox-Gastaut syndrome (LGS), a rare and severe kind of childhood epilepsy characterized by different types of seizures.
These posthoc analysis data were presented at the virtual American Academy of Neurology (AAN) Annual Meeting.
The objective of this posthoc analysis was to assess the impact of the treatment with abilities to self-regulate behavior, emotions, and cognition as part of a 14-week Phase 3 trial in 263 LGS patients aged 2-35 years.
More LGS study patients treated with Fintepla showed improvement in behavior, emotion, and cognitive function in intractable epilepsy and other developmental conditions.
Improvement was statistically significant for cognition (27% vs. 13% placebo, p=0.046) and the composite score (25% vs. 11% placebo, p=0.034), wherein around twice as many patients achieved clinically meaningful improvement.
Fintepla oral solution has been approved by the FDA and the European Medicines Agency and is in development in Japan to treat seizures associated with Dravet syndrome.
The company has two additional late-stage development programs, one in Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency.
Price Action: ZGNX shares are up 2.01% at $19.33 in market trading hours on the last check Thursday.